Affimed N.V. logo

Affimed N.V.

NASDAQ:AFMD

Overview | Financials
Company Name Affimed N.V.
Symbol AFMD
Currency USD
Price 3.31
Market Cap 50,403,025
Dividend Yield 0%
52-week-range 2.24 - 8.95
Industry Biotechnology
Sector Healthcare
CEO Dr. Adi Hoess M.D., Ph.D.
Website https://www.affimed.com

An error occurred while fetching data.

About Affimed N.V.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase

Related Stocks

Y-mAbs Therapeutics, Inc. logo

Y-mAbs Therapeutics, Inc.

YMAB

14.2 USD

SI-BONE, Inc. logo

SI-BONE, Inc.

SIBN

12.81 USD

Computer Programs and Systems, Inc. logo

Computer Programs and Systems, Inc.

CPSI

9.19 USD

GH Research PLC logo

GH Research PLC

GHRS

8 USD

PetMed Express, Inc. logo

PetMed Express, Inc.

PETS

3.97 USD

AirSculpt Technologies, Inc. logo

AirSculpt Technologies, Inc.

AIRS

5.81 USD

PetIQ, Inc. logo

PetIQ, Inc.

PETQ

30.91 USD

Ocugen, Inc. logo

Ocugen, Inc.

OCGN

0.93 USD

Financials

Numbers are in millions USD

Numbers are in millions USD